NEXIUM IV
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEXIUM IV (NEXIUM IV).
Proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Esomeprazole is the S-isomer of omeprazole, which is concentrated in the acidic environment of parietal cells and converted to the active sulfenamide form that binds covalently with the proton pump, leading to irreversible inhibition.
| Metabolism | Extensively metabolized in the liver via CYP2C19 and CYP3A4 isoenzymes. Metabolites include hydroxy, desmethyl, and sulfone conjugates, which are pharmacologically inactive. |
| Excretion | Renal (approx. 80% as inactive metabolites), fecal (approx. 20% as metabolites and parent drug). Less than 1% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is approximately 1-1.5 hours in healthy adults. In patients with hepatic impairment (Child-Pugh Class A, B, or C), half-life may be prolonged up to 2.9-8 hours. |
| Protein binding | Approximately 97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution at steady state (Vdss) is about 0.15 L/kg (range 0.13-0.17 L/kg), indicating minimal extravascular distribution. |
| Bioavailability | Intravenous: 100% (complete bioavailability). Oral (for reference): 50-80% due to first-pass metabolism; IV administration bypasses this. |
| Onset of Action | For intravenous administration: suppression of gastric acid secretion begins within 1 hour after dosing. Maximal effect (80% intragastric pH >4) is achieved by 2-4 hours. |
| Duration of Action | Gastric acid suppression persists for 24 hours with once-daily IV dosing due to prolonged binding to the proton pump. No rebound hypersecretion upon cessation. |
| Molecular Weight | 345.42 |
20-40 mg intravenously once daily; for GERD with erosive esophagitis: 20-40 mg once daily; for Zollinger-Ellison syndrome: 80 mg IV every 12 hours, adjust based on acid output.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; for severe renal impairment (CrCl <30 mL/min), maximum daily dose is 20 mg. |
| Liver impairment | Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment; severe hepatic impairment (Child-Pugh C): maximum daily dose 20 mg. |
| Pediatric use | For GERD in pediatric patients 1 month to <1 year: 0.5 mg/kg IV once daily; 1 to 17 years: weight-based dosing: 10 kg to <20 kg: 10 mg IV once daily; ≥20 kg: 20 mg IV once daily; maximum 40 mg. |
| Geriatric use | No specific dose adjustment required; consider age-related renal impairment and limit to 20 mg IV once daily if severe renal impairment present. |
| 1st trimester | Limited human data; animal studies have not shown fetal risk. Use only if clearly needed. |
| 2nd trimester | Limited human data; no evidence of harm in animal studies. Use if potential benefit justifies risk. |
| 3rd trimester | Limited human data; no evidence of fetal harm. Consider as alternative to oral therapy when IV route needed. |
Clinical note
Comprehensive clinical and safety monograph for NEXIUM IV (NEXIUM IV).
| Placental transfer | Esomeprazole crosses the placenta in animal studies; limited human data suggest transfer occurs. Degree is likely moderate based on molecular weight and protein binding. |
| Breastfeeding | Esomeprazole is excreted in human milk in low concentrations; effects on nursing infant are unknown. Caution advised; consider alternative agents with more safety data (e.g., omeprazole). |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to esomeprazole or substituted benzimidazolesConcomitant use with rilpivirine-containing products
| Precautions | Gastric malignancy risk: Symptomatic response does not preclude presence of gastric malignancy., Acute interstitial nephritis: Discontinue if suspected., Clostridium difficile-associated diarrhea: Increased risk with PPI use., Bone fracture: Long-term/high-dose use may increase risk of osteoporosis-related fractures (hip, wrist, spine)., Hypomagnesemia: Can occur with prolonged use; monitor magnesium levels., Cyanocobalamin (Vitamin B12) deficiency: May reduce absorption with long-term use., Interference with laboratory tests: May cause false elevations in secretin-stimulated gastrin test; discontinue PPI at least 2 weeks before testing., Severe cutaneous adverse reactions: Including Stevens-Johnson syndrome and toxic epidermal necrolysis; discontinue if signs occur. |
| Food/Dietary | No specific food interactions with IV administration. However, for patients transitioning to oral therapy, advise that esomeprazole should be taken at least 1 hour before food. Avoid high-fat meals if switching to oral, as they may delay absorption. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Esomeprazole is classified as FDA Pregnancy Category B. In first trimester, available data from observational studies do not show increased risk of major congenital malformations. In second and third trimesters, no evidence of fetal harm. However, caution is advised as data are limited. |
| Fetal Monitoring | Monitor maternal signs of gastrointestinal bleeding, electrolyte imbalances, and infection risk. Fetal monitoring via ultrasound if prolonged use in pregnancy. Assess infant for lethargy, irritability, or feeding difficulties if used near term. |
| Fertility Effects | No known impairment of fertility in animal studies. Human data limited; esomeprazole is not expected to significantly affect fertility. |
| Clinical Pearls | Administer IV esomeprazole over 10-30 minutes; not to be mixed with other medications in same IV line. For stress ulcer prophylaxis in ICU patients, consider continuous infusion (8 mg/h) after initial 80 mg bolus. Monitor for hypomagnesemia with prolonged use beyond 1 year. Use with caution in severe hepatic impairment (Child-Pugh C); reduce dose to 20 mg/day. May elevate serum chromogranin A levels, potentially interfering with neuroendocrine tumor diagnostics. |
| Patient Advice | Use exactly as prescribed; do not change dose or stop without consulting doctor. · Injections are given by healthcare provider; do not attempt to self-administer. · Report signs of hypomagnesemia: muscle cramps, arrhythmias, seizures, or tetany. · If using for GERD, avoid eating within 2 hours of dose for best effect. · Inform all healthcare providers about current use, including dentists. · Avoid alcohol and NSAIDs to reduce gastric irritation. |